

ImmuPharma

IMM  25.63p ▼ -0.5 -1.9%

Market Cap	£31.8m	Value	1
Enterprise Value	£29.1m	Quality	36
Revenue	£198k	Momentum	28
Position in Universe	1160th / 1809	StockRank™	9

Zoom 1m 3m 6m YTD 1y 2y 3y 5y All



Momentum

Relative Strength (%)	
1m	-9.2%
3m	-5.4%
1yr	-45.0%
Volume Change (%)	
10d v 3m	-48.3%
Price vs... (%)	
52w High	-50.7%
50d MA	+0.077%
200d MA	-17.5%

Growth & Value

12m Forecast Rolling		vs. industry	vs. market
PE Ratio (f)	n/a		
PEG Ratio (f)	n/a		
EPS Growth (f)	n/a	%	
Dividend Yield (f)	n/a	%	
Valuation (ttm)			
Price to Book Value	7.99		
Price to Tang. Book	9.21		
Price to Free Cashflow	n/a		
Price to Sales	160.4		
EV to EBITDA	n/a		

Margin of Safety (beta)

Relative to Sector	-58%
Stability Value (EPV)	-74%

Screens Passed

IMM doesn't qualify for any screens.
Find out why: [View Checklists](#)

Quality

		vs. industry	vs. market
Return on Capital	-73.1 %		
Return on Equity	-69.5 %		
Operating Margin	-1,585 %		

Financial Summary

Balance Sheet • Income Statement • Cashflow

Year End 31st Dec		2009	2010	2011	2012	2013	2014	TTM	2015E	2016E	CAGR / Avg
Revenue	£m	22.1	0.033	0.017	0.000	0.000	0.19	0.20			-61.6%
Operating Profit	£m	10.3	-4.18	-3.84	-4.18	-4.23	-3.42	-3.14			
Net Profit	£m	8.10	-1.98	-3.36	-3.84	-3.69	-2.87	-2.58	-9.00	-10.00	
EPS Reported	p	9.93	-2.44	-4.12	-4.72	-4.52	-3.44	-2.96			
EPS Normalised	p	9.93	-2.44	-4.12	-4.72	-4.52	-3.44	-2.96	-10.4	-11.5	
EPS Growth	%	+73.1									
PE Ratio	x						n/a	n/a	n/a	n/a	
PEG	x						n/a	n/a	n/a	n/a	
Profitability											
Operating Margin	%	46.7	-12,876	-22,766			-1,853	-1,585			-6,241%
ROA	%		-9.4	-21.1	-31.0	-41.7		-43.3			
ROCE	%	55.6	-25.0	-28.8	-44.2	-68.5	-56.3	-73.1			-27.8%
ROE	%		-11.6	-23.6	-36.7	-53.4	-51.7	-69.5			-35.4%
Cashflow											
Op. Cashflow ps	p	14.7	-8.43	-4.13	-3.99	-4.79	-2.98	-2.83			
Capex ps	p	0.006	0.098	0.081	0.016	0.004	0.42	0.025			+138.6%
Free Cashflow ps	p	14.7	-8.53	-4.21	-4.01	-4.80	-3.40	-2.85			
Dividends											
Dividend ps	p										
Dividend Growth	%										
Dividend Yield	%										
Dividend Cover	x										
Balance Sheet											
Cash etc	£m	22.5	15.6	12.2	8.89	5.40	5.42	3.29			-24.8%
Working Capital	£m	17.8	16.0	12.5	8.71	5.47	5.15	3.47			-21.9%
Net Fixed Assets	£m	0.010	0.077	0.13	0.12	0.098	0.37	0.31			+108.4%
Net Debt	£m	-22.1	-14.8	-11.2	-7.61	-4.28	-4.63	-2.68			
Book Value	£m	18.1	16.0	12.5	8.42	5.40	5.71	3.98			-20.6%
Average Shares	m	81.6	81.2	81.5	81.5	81.7	83.6	85.5			+0.5%
Book Value ps	p	22.3	19.6	15.3	10.3	6.57	6.44	4.50			-22.0%

Health Trend

Piotroski F-Score 5



Bankruptcy Risk

Altman Z1-Score 16.4



Earnings Manipulation Risk

N/A

Magic Formula Score

2696 16% E+




Other Ratios

Leverage (ttm)		total	ex intang
Gross Gearing	%	15.4	17.8
Net Gearing	%	-67.3	-77.6
Cash / Assets	%	67.9	
Liquidity (ttm)			
Efficiency (ttm)			
Curr. Ratio	7.32	Asset Turnover	0.034
Quick Ratio	7.32	Rec's Turnover	0.28
Interest Cov.	100.0	Stock Turnover	n/a

Recent History

		vs. industry	vs. market
Latest interim period (ended 30th Jun '15) vs. prior year			
Sales Growth	n/a	%	
EPS Growth	n/a	%	
3yr Compound Annual Growth Rate			
Sales Growth	122.2	%	
EPS Growth	n/a	%	
DPS Growth	n/a	%	

Graphical History Current Fiscal Year 2015



Broker Forecasts


31st Dec 2015

31st Dec 2016

Broker Consensus Trend

1 Brokers

Price Target: N/A	Net Profit	EPS	DPS	Net Profit	EPS	DPS
Est. Long Term Growth Rate: n/a	(£)	(p)	(p)	(£)	(p)	(p)
Consensus Estimate	-9.00m	-10.4	-	-10.00m	-11.5	-
1m Change	-	-	-	-	-	-
3m Change	-	-	-	-	-	-



Profile Summary



ImmuPharma plc (ImmuPharma) is a United Kingdom-based is a drug discovery and development company. Its research operations are in France. The Company is engaged in the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions, such as autoimmune diseases. ImmuPharma is engaged in developing drug candidates for five different medical conditions. ImmuPharma's lead product candidate, Lupuzor, focuses on Lupus disease. The other four drug candidates address cancer, moderate to severe pain (such as that experienced by cancer sufferers and post-operative patients), methicillin-resistant staphylococcus aureus (MRSA) and severe hospital-acquired resistant infections and inflammation/allergic disorders. The Lupuzor has completed the phase IIb clinical study. IPP-204106 is ImmuPharma's anti-cancer nucleolin/nucleophosmin antagonist (Nucant) peptide program.

Directors: Robert Zimmer (PRE), Dimitri Dimitriou (CEO), Tracy Weimar (VFN), Timothy McCarthy (NEC) 58, Stephane Mery (NED) 50,

No. of Employees: 10


No. of Shareholders: n/a

Last Annual December 31st, 2014
Last Interim June 30th, 2015

Incorporated February 21, 2000
Public Since October 28, 2003

Shares in Issue 121,781,219
Free Float 77.5m (63.7%)

Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Eligible for an ISA? ✓ a SIPP? ✓



Address 50 Broadway, WESTMINSTER, SW1H 0RG, United Kingdom
Web <http://www.immupharma.com>
Phone +44 20 71524080
Contact ()
Auditors Nexia Smith & Williamson

IMMQuote

IMM Share Price
GBP

25.63p

Traded 4:04pm · Minimum 15 min delayed · NMS: 10.00k

Day's Change

▼ -0.5 -1.9%

Volume
303,800

Avg Vol (3m)
129,461

Bid - Ask
24.5 - 26.8

Open - Close
25.0 - 25.6


Low - High
25.0 - 26.8

12m Range
25.0 - 28.0

Spread
878bps

Beta
-0.14

IMM Share Price Performance



Latest IMM News Announcements (delayed)

[More »](#)

9th Mar [First European Site Opens - Patient Recr...](#)
8th Mar [Holding\(s\) in Company](#)
7th Mar [Holding\(s\) in Company](#)
1st Mar [EIS and VCT Qualifying Status and Issue...](#)
29th Feb [Holding\(s\) in Company](#)

Upcoming IMM Events

Friday 27th May, 2016 (Estimate)

ImmuPharma PLC Annual Shareholders Meeting

Recent ↓

Industry Peer Group

Abzena
[Compare vs IMM](#)
Silence Therapeuti...
[Compare vs IMM](#)
ReNeuron
[Compare vs IMM](#)
Oxford BioMedica
[Compare vs IMM](#)
Horizon Discovery
[Compare vs IMM](#)
Tissue Regenix
[Compare vs IMM](#)
Vernalis
[Compare vs IMM](#)
Verseon
[Compare vs IMM](#)

[Healthcare](#)

[Biotechnology & Medical Research](#)

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2016.